10 matches for your search in the start-up spotlight
rss
04-Jan-2024
Evotec SE and Owkin, a French-American techbio startup announced an A.I.-powered integrated multi-target collaboration in oncology, immunology and inflammation (“I&I”). The collaboration brings together highly complementary platforms and expertise to accurately select targets, discover and ...
Agreement is based on a risk-sharing arrangement followed by milestone and royalty payments to Evotec based on success of overall programmes
08-Nov-2023
Evotec SE and Dewpoint Therapeutics announced a strategic R&D collaboration to advance Dewpoint’s leading oncology pipeline programmes of condensate modifying therapeutics (“c-mods”) to Investigational New Drug Applications (“INDs”) using Evotec’s industry-leading fully integrated data-driven ...
Evotec, ClavystBio, Leaps by Bayer, Lightstone Ventures and Polaris Partners launch "65LAB"
06-Oct-2023
Evotec SE announced that the Company has entered into a new BRIDGE partnership with Lightstone Ventures, ClavystBio, Leaps by Bayer, Polaris Partners, and the Polaris Innovation Fund. “65LAB”, Evotec’s first academic BRIDGE in Asia, aims to advance drug discovery and the creation of new ...
31-May-2022
Evotec SE announced the signing of a definitive agreement under which Evotec will acquire 100% of the capital of Rigenerand Srl, a leading cell technology company, for a purchase price of € 23 m. Founded in 2009 as a spin-off of the University of Modena and Reggio Emilia, Rigenerand is a ...
Biotech startup aims to deliver important new therapies to patients at more affordable prices
22-Nov-2021
Evotec SE and EQRx, a new type of pharmaceutical company committed to developing and delivering important new medicines to patients at radically lower prices, announced a collaboration to design, discover and develop new therapeutic options for patients. The collaboration will help accelerate ...
Exosomes are a promising novel approach for innovative regenerative therapies, as therapeutics in age-related conditions, but also for diagnostic purposes
10-Dec-2020
Evotec SE Sartorius announced that they have entered into a partnership with the recently established Curexsys GmbH, a Goettingen, Germany-based technology leader specialising in the emerging field of therapeutic exosomes. Curexsys delivers a proprietary isolation technology for exosomes based on ...
Quantro exploits innovative functional-genetic and transcriptomic technologies to address “undruggable” targets
22-Jul-2020
Evotec SE announced that the Company has entered into a comprehensive partnership with the recently established QUANTRO Therapeutics GmbH, a research-based biotech company based in Vienna, Austria, that strives to discover and develop novel therapeutics interfering with disease-causing ...
Evotec participates in Exscientia's financing round
29-May-2020
Evotec SE announced that the Company has participated in the Series C funding round of Exscientia, the Artificial Intelligence (AI)-driven drug discovery company. The funding round led by new investor Novo Holdings raised $ 60 m with the existing investors’ consortium consisting of Evotec, ...
Early stage funding amounting to € 30 m
09-Jul-2019
Evotec SE announced the formation of Breakpoint Therapeutics GmbH, a spin-off company focusing on the development of Evotec’s DNA damage response (“DDR”) portfolio, comprising discovery-stage assets and drug targets that promise broad therapeutic application in a variety of cancers. Breakpoint ...
25-Jun-2019
Evotec SE announced that it has entered into a new strategic partnership with the British clinical AI technology company Sensyne Health plc, the University of Oxford, Oxford University Innovation Ltd (“OUI”, the university's research commercialisation company), and Oxford Sciences Innovation ...
